Oral Propranolol for Surgically Inaccessible Cerebral and Spinal Cavernous Malformations

Principal Investigator: Yashar Kalani
Keywords: Cavernous Malformation , Propranolol Department: Neurosurgery
IRB Number: 00095783 Co Investigator:  
Specialty: Neurosurgery
Sub Specialties: Neurovascular Surgery
Recruitment Status: Recruiting

Contact Information

Yashar Kalani
yashar.kalani@hsc.utah.edu
801-585-6789

Brief Summary

Cerebral cavernous malformations are more common than generally thought, affecting approximately 1 in every 250 adults. Most of these lesions are asymptomatic or have a relatively benign course, but a small minority behave aggressively and present with recurrent episodes of symptomatic hemorrhage. A safe and effective medical treatment option for the management of this latter group would be useful. Propranolol has recently been shown to be effective in the treatment of infantile hemangioma, a close pathologic counterpart of cavernous malformations. These results suggest a potential role for propranolol treatment in the management of patients with symptomatic cavernous malformations. We seek to conduct a clinical trial of oral propranolol for treatment of surgically inaccessible cerebral and spinal cavernous malformations. 

Inclusion Criteria

All patients with documented cerebral or spinal cavernous malformations not amenable to safe surgical resection.

Exclusion Criteria

Patients with spinal or cerebral cavernous malformations that are surgically accessible with acceptable morbidity, meaning that they arise to a pial or ependymal surface.